Immunotherapies and Renal Injury

Overview

Journal Curr Opin Toxicol

Date 2024 Aug 1

PMID 39086475

Authors

Aisha Shaikh

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy represents a giant leap forward in the management of malignant diseases. An optimal anti-tumor immune response requires cancer antigen recognition by T-cells followed by an effector immune response. Suppression of T-cell activation prevents cancer cell clearance resulting in tumor proliferation. Recent clinical successes of immune checkpoint inhibitors and chimeric antigen receptor T cell therapies has transformed the landscape of cancer immunotherapy. The goal of immunotherapy is to boost host-protective anti-tumor immunity without concomitantly causing immune-related adverse events. However, immunotherapies can cause multiorgan dysfunction including acute kidney injury. Prompt recognition and management of immunotherapy-associated kidney injury is critical in preserving kidney function and improving patient outcomes.

References

Mamlouk O, Nair R, Iyer S, Edwards A, Neelapu S, Steiner R . Safety of CAR T-cell therapy in kidney transplant recipients. Blood. 2021; 137(18):2558-2562. PMC: 8109014. DOI: 10.1182/blood.2020008759. View

Fife B, Bluestone J . Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008; 224:166-82. DOI: 10.1111/j.1600-065X.2008.00662.x. View

Krishnamoorthy S, Ghobadi A, Santos R, Schilling J, Malone A, Murad H . CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. Am J Transplant. 2020; 21(2):809-814. DOI: 10.1111/ajt.16367. View

Thompson J, Schneider B, Brahmer J, Andrews S, Armand P, Bhatia S . Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019; 17(3):255-289. DOI: 10.6004/jnccn.2019.0013. View

Isik B, Alexander M, Manohar S, Vaughan L, Kottschade L, Markovic S . Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. Kidney Int Rep. 2021; 6(4):1022-1031. PMC: 8071627. DOI: 10.1016/j.ekir.2021.01.013. View

Abdel-Wahab N, Safa H, Abudayyeh A, Johnson D, Trinh V, Zobniw C . Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019; 7(1):106. PMC: 6469201. DOI: 10.1186/s40425-019-0585-1. View

Krummel M, Allison J . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182(2):459-65. PMC: 2192127. DOI: 10.1084/jem.182.2.459. View

Iwai Y, Hamanishi J, Chamoto K, Honjo T . Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017; 24(1):26. PMC: 5381059. DOI: 10.1186/s12929-017-0329-9. View

Fadel F, Karoui K, Knebelmann B . Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009; 361(2):211-2. DOI: 10.1056/NEJMc0904283. View

10.

Lee M, Seethapathy H, Strohbehn I, Zhao S, Boland G, Fadden R . Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J Immunother Cancer. 2021; 9(4). PMC: 8051410. DOI: 10.1136/jitc-2020-002292. View

11.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

12.

. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2016; 374(10):998. DOI: 10.1056/NEJMx160005. View

13.

Qualls D, Seethapathy H, Bates H, Tajmir S, Heidari P, Endres P . Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. J Immunother Cancer. 2019; 7(1):356. PMC: 6925427. DOI: 10.1186/s40425-019-0820-9. View

14.

Centanni M, Moes D, Troconiz I, Ciccolini J, van Hasselt J . Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019; 58(7):835-857. PMC: 6584248. DOI: 10.1007/s40262-019-00748-2. View

15.

Hong M, Clubb J, Chen Y . Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell. 2020; 38(4):473-488. DOI: 10.1016/j.ccell.2020.07.005. View

16.

Herrmann S, Alexander M, Romero M, Zand L . Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor-A Report of 3 Cases. Kidney Med. 2020; 2(5):657-662. PMC: 7568062. DOI: 10.1016/j.xkme.2020.05.015. View

17.

Belliere J, Mazieres J, Meyer N, Chebane L, Despas F . Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics (Basel). 2021; 11(7). PMC: 8303282. DOI: 10.3390/diagnostics11071187. View

18.

Garcia-Carro C, Bolufer M, Bury R, Castaneda Z, Munoz E, Felip E . Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant. 2021; 37(5):887-894. DOI: 10.1093/ndt/gfab034. View

19.

Kitchlu A, Jhaveri K, Wadhwani S, Deshpande P, Harel Z, Kishibe T . A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep. 2021; 6(1):66-77. PMC: 7783581. DOI: 10.1016/j.ekir.2020.10.002. View

20.

Seethapathy H, Rusibamayila N, Chute D, Lee M, Strohbehn I, Zubiri L . Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2020; 36(12):2241-2247. PMC: 8643613. DOI: 10.1093/ndt/gfaa272. View